Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

Summary

This trial adopts a randomized, double-blind, positive drug-controlled, dose-escalated phase Ib clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary effectiveness of recombinant human serum albumin in patients with liver cirrhosis and ascites subjects (both male and female) were screened and enrolled to the three dose levels of 10g, 20 g,and 30 g according to the principle of dose escalation, and 8 out of 12 subjects in each dose group One patient received the test drug, and 4 received a positive drug.

Timeline

Start

2021-10-14

Primary completion

2022-05-16

Completion

2022-05-16

Drugs

Indications

No indication recorded.